Cardiology Flashcards

1
Q

What is ischaemic heart disease

A
  • Term used to describe heart problems caused by narrowed coronary arteries which leads to cardiac myocyte damage
  • MI + angina
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is stable angina

A

Chest pain caused by an insufficient blood supply to the myocardium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Give 3 characteristics of stable angina

A
  • Central constricting chest pain that may radiate to arms/jaw
  • Brought on by exertion of stress
  • always relieved by rest or GTN (glyceryl trinitrate)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

3 non-modifiable RFs of ischaemic heart disease

A
  • Increasing age
  • Male gender
  • Family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

5 modifiable RFs of ischaemic heart disease

A
  • Smoking
  • Diabetes mellitus
  • Hypertension
  • Hypercholesterolaemia
  • Obesity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the investigations and diagnosis of stable angina

A

1st line = ECG - Normal or ST depression
GS: CT Angiography - stenosed atherosclerotic arteries (70-80% occluded)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is stable angina managed

A
  • All patients: statin + aspirin in the absence of contraindications
  • Lifestyle: smoking cessation, exercise, weight loss
  • sublingual glyceryl trinitrate to abort angina attacks
  • 1st: beta blocker or CCB monotherapy
  • 2nd: if patient is still symptomatic with monotherapy, add the other drug i.e. BB + CCB
  • revascularisation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When managing stable angina, if a patient is on monotherapy and cannot tolerate the addition of a CCB or a BB what drugs should be added

A

One of the following:
* a long-acting nitrate (Isosorbide mononitrate)
* ivabradine
* nicorandil
* ranolazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When managing stable angina, what calcium channel blockers should be used as monotherapy

A

rate limiting:
* verapamil
* diltiazem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When managing stable angina, what calcium channel blockers should be prescribed when combined with a beta blocker

A

Longer-acting dihydropyridine CCB:
* amlodipine
* modified-release nifedipine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the 2 types of coronary revascularisation

A
  • PCI (Percutaneous coronary intervention): balloon stent. Less invasive but risk of stenosis
  • CABG (coronary artery bypass graft): bypass graft. Has better prognosis but is more invasive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What physical sign identifies a patient who’s had a previous CABG

A

A midline sternotomy scar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is acute coronary syndrome

A

Umbrella term covering acute presentations of IHD, including:
* Unstable angina
* ST elevation MI (STEMI)
* Non-ST elevation MI (NSTEMI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does acute coronary syndrome present

A
  • central constricting chest pain that may radiate to the jaw or the left arm
  • dyspnoea
  • sweating
  • palpitations
  • nausea and vomiting
  • typically last over 20 minutes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is silent myocardial infarction and who are they more likely to be seen in

A
  • May not experience any chest pain during an ACS
  • More likely in the elderly, females and diabetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is acute coronary syndrome investigated

A
  • ECG
  • cardiac markers e.g. troponin
  • CT coronary angiogram - extent of occlusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ECG changes in leads V1-V4 would indicate damage to which coronary artery

A

Left anterior descending

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ECG changes in leads II, III, aVF would indicate damage to which coronary artery

A

Right coronary (inferior)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

ECG changes in leads I, V5-6 would indicate damage to which coronary artery

A

Left circumflex (lateral)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What investigation results would indicate unstable angina

A
  • ECG: normal or may show changes indicative of ischaemia
  • Troponin: normal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What investigation results would indicate a NSTEMI

A
  • ECG: ST depression, pathological Q waves and T wave inversion
  • Troponin: Raised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What investigation results would indicate a STEMI

A
  • ECG: ST elevation in leads consistent with an area of ischaemia / new LBBB
  • Raised troponin
  • Complete occlusion of a major coronary artery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the common management of all patients with acute coronary syndrome

A

MONA
* morphine - only if severe pain
* oxygen - only if O2 sats < 94%
* Nitrates: sublingually or IV (should be used in caution if patient hypotensive)
* Aspirin 300mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the first step of management once a STEMI has been confirmed?

A

Immediately assess eligibility for coronary reperfusion therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the two types of coronary reperfusion therapy?

A
  • Percutaneous coronary intervention (PCI)
  • Fibrinolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

When should percutaneous coronary intervention be offered for STEMI?

A

If the presentation is within 12 hours of symptom onset and PCI can be delivered within 120 minutes of when fibrinolysis could have been given

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What type of stents are used in percutaneous coronary intervention for STEMI?

A

Drug-eluting stents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What type of access is preferred for Percutaneous Coronary Intervention?

A

Radial access

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

When should fibrinolysis be offered for STEMI?

A

Within 12 hours of symptom onset if Percutaneous Coronary Intervention cannot be delivered within 120 minutes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What should be done if an ECG 90 minutes after fibrinolysis shows no resolution of ST elevation?

A

The patient should be transferred for Percutaneous Coronary Intervention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What dual antiplatelet therapy should be given prior to Percutaneous Coronary Intervention?

A

aspirin + another drug:
* if patient not taking an oral anticoagulant: prasugrel
* if taking an oral anticoagulant: clopidogrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the recommended drug therapy for patients during Percutaneous Coronary Intervention

A
  • radial access: Unfractionated heparin with bailout glycoprotein IIb/IIIa inhibitor
  • femoral access: bivalirudin with bailout GPI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What should be given to patients undergoing fibrinolysis for STEMI?

A

antithrombin drug (e.g. alteplase + Fondaparinux)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

When should an ECG be repeated after fibrinolysis for STEMI?

A

After 60-90 minutes to check for resolution of the ECG changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is the initial management once a NSTEMI/ unstable angina is identified

A

aspirin 300mg and one other drug:
* no bleeding risk/ no immediate PCI planned: Fondaparinux.
* immediate PCI planned/ creatinine >265 µmol/L: Unfractionated heparin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is the most widely used tool for risk assessment in NSTEMI and unstable angina?

A

The Global Registry of Acute Coronary Events (GRACE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What key decisions are made based on the risk assessment in NSTEMI/unstable angina?

A

Decisions are made regarding whether the patient should undergo coronary angiography (with follow-on PCI if necessary) or receive conservative management.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Which patients with NSTEMI/unstable angina should have immediate coronary angiography?

A

Patients who are clinically unstable (e.g., hypotensive).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Which patients with NSTEMI/unstable angina should have coronary angiography within 72 hours?

A

Patients with a GRACE score greater than 3%, i.e., those at intermediate, high, or highest risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What is the role of Percutaneous Coronary Intervention for patients with NSTEMI/unstable angina?

A

It is performed when coronary angiography reveals significant coronary artery disease, and the procedure can restore blood flow if needed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What further drug therapy is given to patients undergoing Percutaneous Coronary Intervention for NSTEMI/unstable angina?

A
  • Unfractionated heparin (regardless of prior fondaparinux use)
  • Dual antiplatelet therapy - aspirin + another drug:
    if the patient is not taking an oral anticoagulant - prasugrel or ticagrelor
    if taking an oral anticoagulant - clopidogrel
42
Q

What further drug therapy is given to patients managed conservatively for NSTEMI/unstable angina?

A

Dual antiplatelet therapy I.E. aspirin + another drug:
* if the patient is not at a high risk of bleeding: ticagrelor
* if the patient is at a high risk of bleeding: clopidogrel

43
Q

Give 3 poor prognostic factors in acute coronary syndrome

A
  • cardiogenic shock
  • age
  • development/ history of heart failure
44
Q

Complications of myocardial infarction

A
  • Cardiac arrest
  • Cardiogenic shock
  • Tachyarrhythmias - Ventricular fibrillation
  • Bradyarrhythmias - AV block is mc following inferior MI
  • Pericarditis
  • Dressler’s syndrome
45
Q

Following a myocardial infarction, what should all patients be offered as secondary prevention

A
  • Dual antiplatelet therapy: Aspirin + prasugrel or ticagrelor. stop second antiplatelet after 12 months
  • ACE inhibitor
  • beta-blocker
  • statin
46
Q

What is heart failure

A

clinical syndrome where the heart is unable to pump enough blood to meet the metabolic needs of the body

47
Q

Describe HF with reduced ejection fraction

A
  • left ventricular ejection fraction < 35 to 40%
  • systolic dysfunction
48
Q

Describe HF with preserved ejection fraction

A
  • left ventricular ejection fraction >50%
  • diastolic dysfunction
49
Q

Give 4 conditions that cause diastolic dysfunction

A

Hypertrophic obstructive cardiomyopathy
Restrictive cardiomyopathy
Cardiac tamponade
Constrictive pericarditis

50
Q

Give 4 conditions that cause systolic dysfunction

A

Ischaemic heart disease
Dilated cardiomyopathy
Myocarditis
Arrhythmias

51
Q

Signs of left ventricular failure

A
  • pulmonary oedema
  • dyspnoea
  • orthopnoea
  • paroxysmal nocturnal dyspnoea
  • bibasal fine crackles
52
Q

Signs of right ventricular failure

A
  • peripheral oedema: ankle/sacral oedema
  • raised jugular venous pressure
  • hepatomegaly
  • weight gain due to fluid retention
  • anorexia (‘cardiac cachexia’)
53
Q

What is high output heart failure

A

where a ‘normal’ heart is unable to pump enough blood to meet the metabolic needs of the body

54
Q

3 causes of high output heart failure

A
  • severe anaemia
  • pregnancy
  • thyrotoxicosis
55
Q

What is de-novo acute heart failure?

A

De-novo acute heart failure occurs without a previous history of heart failure

56
Q

What is decompensated acute heart failure?

A

occurs in patients with a history of chronic heart failure and accounts for the majority (66-75%) of acute heart failure cases.

57
Q

At what age does acute heart failure typically present?

A

after the age of 65

58
Q

What causes de-novo acute heart failure?

A

often caused by increased cardiac filling pressures and myocardial dysfunction, usually due to ischaemia

59
Q

What are the most common precipitating causes of decompensated acute heart failure?

A
  • Acute coronary syndrome
  • Hypertensive crisis
  • Acute arrhythmia
  • Valvular disease
60
Q

What are the general symptoms of acute heart failure?

A
  • Breathlessness
  • Reduced exercise tolerance
  • Oedema
  • Fatigue
61
Q

What are the signs of acute heart failure?

A
  • Cyanosis
  • Tachycardia
  • Elevated jugular venous pressure
  • Displaced apex beat
  • Bibasal crackles or wheeze
  • S3 heart sound (LHF)
62
Q

What is the most common blood pressure finding in patients with acute heart failure?

A

Over 90% of patients with acute heart failure have normal or increased blood pressure.

63
Q

Investigations for acute heart failure?

A
  • Blood tests: check for anaemia, electrolyte abnormalities, or infection
  • Chest XR: look for pulmonary venous congestion, interstitial oedema, and cardiomegaly
  • Echocardiogram
  • B-type natriuretic peptide: raised levels >100mg/litre indicate myocardial damage
64
Q

When is an ECHO indicated in the investigation of acute HF

A
  • new-onset HF
  • cardiogenic shock
  • suspected valvular problems
  • post-myocardial infarction complications
65
Q

Features of chronic heart failure

A
  • cough: may be worse at night and associated with pink/frothy sputum
  • orthopnoea
  • paroxysmal nocturnal dyspnoea
  • wheeze (due to pulmonary oedema)
  • weight loss
  • bibasal crackles on examination
  • signs of right-sided heart failure
66
Q

What is the recommended treatment for all patients with acute heart failure?

A

Intravenous loop diuretics (e.g., furosemide or bumetanide).

67
Q

What is the recommended oxygen target for patients with acute heart failure?

A

Oxygen should be administered to keep oxygen saturations at 94-98%

68
Q

When should vasodilators like nitrates be used in acute heart failure?

A

if there is concomitant myocardial ischaemia, severe hypertension, or regurgitant aortic or mitral valve disease

69
Q

What is the treatment for patients with respiratory failure due to acute heart failure?

A

Continuous positive airway pressure (CPAP).

70
Q

How should acute heart failure with hypotension (e.g., < 85 mmHg) or cardiogenic shock be managed?

A
  • inotropic agents (e.g., dobutamine) -severe left ventricular dysfunction
  • Vasopressor agents (e.g., norepinephrine)
  • mechanical circulatory assistance
71
Q

What should be done with regular heart failure medications in patients with acute heart failure?

A

Regular heart failure medications, such as beta-blockers and ACE inhibitors, should be continued unless contraindicated.

72
Q

When should beta-blockers be stopped in patients with acute heart failure?

A

if the patient has a heart rate of less than 50 beats per minute, second or third degree atrioventricular block, or shock.

73
Q

What is atrial fibrillation

A

most common sustained cardiac arrhythmia, characterised by an irregularly irregular pulse and an increased risk of stroke, particularly in older patients

74
Q

What are the types of atrial fibrillation?

A
  • First detected episode – first time AF is diagnosed.
  • Paroxysmal AF – episodes of AF that terminate spontaneously, usually within 24 hours (but less than 7 days).
  • Persistent AF – AF episodes that last more than 7 days and do not self-terminate.
  • Permanent AF – continuous AF that cannot be cardioverted or when attempts are deemed inappropriate.
75
Q

What are the typical symptoms of atrial fibrillation?

A

Palpitations
Dyspnoea
Chest pain

76
Q

What is the key sign of atrial fibrillation?

A

An irregularly irregular pulse.

77
Q

What is the primary investigation for diagnosing atrial fibrillation?

A

An ECG - diagnose AF and differentiate it from other conditions with an irregular pulse, such as ventricular ectopics or sinus arrhythmia.

78
Q

ECG signs of AF

A
  • Irregular and rapid QRS complexes (<120ms)
  • Absent P waves
79
Q

What are the two key management goals for atrial fibrillation?

A
  • Rate or rhythm control.
  • Reducing stroke risk.
80
Q

What is the difference between rate control and rhythm control in AF management?

A
  • Rate control: Accepting an irregular pulse but using medications to slow the heart rate (first-line treatment).
  • Rhythm control: Attempting to restore normal sinus rhythm, using either pharmacological or electrical cardioversion.
81
Q

What is the preferred approach to atrial fibrillation management according to NICE?

A

Rate control should be offered as the first-line treatment strategy for most patients with atrial fibrillation

82
Q

When is rate control not first line in the management of atrial fibrillation

A
  • AF has a reversible cause
  • HF primarily caused by atrial fibrillation
  • new-onset atrial fibrillation (< 48 hours)
  • with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm
  • when a rhythm-control strategy would be more suitable based on clinical judgement
83
Q

What drugs are used for rate control in atrial fibrillation?

A
  • Beta-blockers (e.g., metoprolol).
  • calcium channel blockers (diltiazem)
  • If additional control is needed, combination therapy with digoxin may be used.
84
Q

When should rhythm control be considered in atrial fibrillation?

A

may be considered in patients with persistent symptoms, or in those who initially started with rate control but continue to experience symptoms or high heart rates

85
Q

What is the management approach for atrial fibrillation (AF) with onset < 48 hours?

A
  • heparinised
  • If the patient has RFs for ischaemic stroke, initiate lifelong oral anticoagulation.
    cardioverted using either:
  • electrical - ‘DC cardioversion’
  • pharmacology - amiodarone if structural heart disease, flecainide or amiodarone in those without structural heart disease
  • Post-cardioversion: no further anticoagulation is required
86
Q

What is the management for atrial fibrillation (AF) with onset > 48 hours?

A
  • rate control initially
  • if considered for long term rhythm control: stable on Anticoagulation for at least 3 weeks prior to cardioversion.
87
Q

What drugs are used for long term rhythm control in atrial fibrillation

A
  • beta-blockers
  • dronedarone: second-line in patients following cardioversion
  • amiodarone: particularly if coexisting heart failure
88
Q

What should be done for patients with atrial fibrillation who present with signs of haemodynamic instability (e.g., hypotension or heart failure)?

A

should be electrically cardioverted

89
Q

What criteria must be fulfilled before attempting cardioversion in atrial fibrillation?

A

Patients must either have had AF for less than 48 hours or be adequately anticoagulated for a period of time to reduce the risk of stroke from embolism.

90
Q

How is the stroke risk in atrial fibrillation assessed?

A

The CHA2DS2-VASc score is used to stratify stroke risk and determine the need for anticoagulation.

91
Q

How is anticoagulation determined based on the CHA2DS2-VASc score?

A
  • Score 0: No treatment (for males).
  • Score 1: Consider anticoagulation (for males), no treatment (for females).
  • Score 2 or more: Offer anticoagulation.
92
Q

What anticoagulants are typically offered to patients with atrial fibrillation?

A
  • 1st: direct oral anticoagulants (DOACs)
  • 2nd: warfarin
93
Q

Give 4 DOACs used for reducing stroke risk in atrial fibrillation

A

apixaban
dabigatran
edoxaban
rivaroxaban

94
Q

In AF, if a CHA2DS2-VASc score suggests no need for anticoagulation what imaging should be done and why

A

ensure a transthoracic echocardiogram has been done to exclude valvular heart disease, which in combination with AF is an absolute indication for anticoagulation.

95
Q

What does NICE recommend regarding anticoagulation in patients, particularly older adults or those at risk of falls?

A

warns against withholding anticoagulation solely based on age or risk of falls. Anticoagulation decisions should still be made based on a thorough risk assessment.

96
Q

What tool is used to formally assess bleeding risk in patients who may be considered for anticoagulation therapy

A

Orbit score

97
Q

What does NICE recommend for long-term stroke prevention in patients with atrial fibrillation post-stroke or TIA?

A

warfarin or a direct thrombin inhibitor or factor Xa inhibitor (DOACs) for long-term stroke prevention.

98
Q

When should anticoagulation be started for a patient with atrial fibrillation after a transient ischaemic attack (TIA)?

A

Anticoagulation should be started immediately following a TIA, once imaging has excluded haemorrhage.

99
Q

When should anticoagulation therapy be started for patients with atrial fibrillation following an acute stroke?

A
  • For acute stroke patients, anticoagulation should be started 2 weeks after the stroke, in the absence of haemorrhage
  • Antiplatelet therapy should be used in the intervening period
100
Q

Give 5 causes of atrial fibrillation

A

S – Sepsis
M – Mitral valve pathology (stenosis or regurgitation)
I – Ischaemic heart disease
T – Thyrotoxicosis
H – Hypertension